NCT01796366View on ClinicalTrials.gov

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 21, 2013

Primary Completion Date

August 19, 2013

Study Completion Date

August 19, 2013

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

insulin 338 (GIPET I)

Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.

DRUG

placebo

S.c placebo administered in combination with insulin 338

DRUG

insulin glargine

Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.

DRUG

placebo

Oral placebo administered in combination with s.c. insulin glargine

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01796366 - A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter